Department of Rheumatology and Immunology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
J Clin Lab Anal. 2021 Apr;35(4):e23709. doi: 10.1002/jcla.23709. Epub 2021 Feb 6.
This study aimed to investigate the relationship of serum JNK pathway-associated phosphatase (JKAP) expression with rheumatoid arthritis (RA) risk and clinical features, also to explore the longitudinal change of JKAP during etanercept treatment and its relationship with etanercept treatment response in RA patients.
A total of 87 RA patients and 44 healthy controls (HCs) were enrolled; then, their JKAP expression in serum was determined by enzyme-linked immunosorbent assay (ELISA). Among 87 RA patients, 42 cases further received the 24-week etanercept treatment; then, their JKAP level in serum (detected by ELISA) and clinical response (evaluated by disease activity score in 28 joints (DAS28) score) were evaluated at week 4 (W4), week 12 (W12), and week 24 (W24) after initiation of etanercept treatment.
JKAP expression was decreased in RA patients compared to HCs, which disclosed a good predictive value for RA risk. JKAP expression was negatively associated with tender joint count, swollen joint count, erythrocyte sedimentation rate, C-reactive protein, and DAS28 in RA patients, respectively. For RA patients who received 24-week etanercept treatment, their clinical response rate was 0.0%, 33.3%, 50.0%, and 69% at W0, W4, W12, and W24, respectively. Importantly, JKAP was gradually increased during etanercept treatment, whose longitudinal elevation positively related to etanercept treatment response in RA patients.
Circulating JKAP links with decreased RA risk and mild disease activity, whose longitudinal elevation positively relates to etanercept treatment response.
本研究旨在探讨血清 JNK 通路相关磷酸酶（JKAP）表达与类风湿关节炎（RA）风险及临床特征的关系，同时探索 JKAP 在依那西普治疗期间的纵向变化及其与 RA 患者依那西普治疗反应的关系。
共纳入 87 例 RA 患者和 44 例健康对照者（HCs），采用酶联免疫吸附试验（ELISA）检测其血清 JKAP 表达。在 87 例 RA 患者中，42 例进一步接受 24 周依那西普治疗，治疗后第 4 周（W4）、第 12 周（W12）和第 24 周（W24），采用 ELISA 法检测血清 JKAP 水平，并评估临床反应（采用 28 个关节疾病活动评分（DAS28）评估）。
与 HCs 相比，RA 患者的 JKAP 表达降低，对 RA 风险具有良好的预测价值。在 RA 患者中，JKAP 表达与压痛关节数、肿胀关节数、红细胞沉降率、C 反应蛋白和 DAS28 分别呈负相关。接受 24 周依那西普治疗的 RA 患者，其临床反应率分别为 0.0%、33.3%、50.0%和 69%，W0、W4、W12 和 W24。重要的是，JKAP 在依那西普治疗期间逐渐升高，其纵向升高与 RA 患者依那西普治疗反应呈正相关。
循环 JKAP 与降低 RA 风险和轻度疾病活动相关，其纵向升高与依那西普治疗反应呈正相关。
